Stock Events

Stock Events

Alto Neuroscience 

$36.40
24
-$0.24-0.66% Thursday 20:00
+$0.00+0%Thursday 20:01After hours

Statistics

Day High
36.4
Day Low
36.12
52W High
37.48
52W Low
3.41
Volume
21,212
Avg. Volume
-
Mkt Cap
1.43B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.8
-0.71
-0.61
-0.52
Expected EPS
-0.672736
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2022
2023
2024
2025
0Revenue
-63.24MNet Income

Analyst Ratings

38.00Average Price Target
The highest estimate is 55.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
83%
Hold
17%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ANRO. It's not an investment recommendation.
Microsoft
6
MSFT
NVIDIA
6
NVDA
Amazon
5
AMZN
Alphabet
5
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Axsome Therapeutics
AXSM
Mkt Cap10.42B
Axsome Therapeutics develops therapies for central nervous system disorders, overlapping with Alto Neuroscience's focus on psychiatric and neurological conditions.
BridgeBio Pharma
BBIO
Mkt Cap14.97B
BridgeBio Pharma targets genetic diseases and genetically defined cancers, including neurological disorders, competing in the precision medicine field like Alto Neuroscience.
Alkermes
ALKS
Mkt Cap7.95B
Alkermes plc works on central nervous system (CNS) disorders, including treatments for mental health issues which is a key area for Alto Neuroscience.
Acadia Pharmaceuticals
ACAD
Mkt Cap5.02B
Acadia Pharmaceuticals specializes in CNS disorders, with a strong focus on neuroscience, making it a direct competitor in the neurotherapeutics field.
AMGEN
AMGN
Mkt Cap233.78B
Amgen has a broad portfolio that includes neuroscience treatments, competing with Alto Neuroscience in developing novel therapies for neurological conditions.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses extensively on neurology and multiple sclerosis, overlapping with Alto Neuroscience's focus on neurological diseases.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly has a significant presence in the neurodegeneration and psychiatric treatment market, positioning it as a competitor in the neuroscience field.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a diversified portfolio that includes treatments for neurological disorders, competing with Alto Neuroscience in the broader neuroscience pharmaceuticals market.

About

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Show more...
CEO
Amit Etkin
Employees
68
Country
United States
ISIN
US02157Q1094

Listings

XNYS
US
ANRO
BOATS
BOATS
ANRO.BOATS

0 Comments

Share your thoughts

FAQ

What is Alto Neuroscience stock price today?▼
The current price of ANRO is $36.40 USD — it has decreased by -0.66% in the past 24 hours. Watch Alto Neuroscience stock price performance more closely on the chart.
What is Alto Neuroscience stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNYS exchange Alto Neuroscience stocks are traded under the ticker ANRO.
Is Alto Neuroscience stock price growing?▼
ANRO stock has risen by +0.28% compared to the previous week, the month change is a +28.94% rise, over the last year Alto Neuroscience has showed a +937.04% increase.
What is Alto Neuroscience market cap?▼
Today Alto Neuroscience has the market capitalization of 1.43B
When is the next Alto Neuroscience earnings date?▼
Alto Neuroscience is going to release the next earnings report on November 11, 2026.
What were Alto Neuroscience earnings last quarter?▼
ANRO earnings for the last quarter are -0.65 USD per share, whereas the estimation was -0.73 USD resulting in a +11.51% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Alto Neuroscience revenue for the last year?▼
Alto Neuroscience revenue for the last year amounts to 0 USD.
What is Alto Neuroscience net income for the last year?▼
ANRO net income for the last year is -63.24M USD.
How many employees does Alto Neuroscience have?▼
As of September 04, 2026, the company has 68 employees.
In which sector is Alto Neuroscience located?▼
Alto Neuroscience operates in the Health & Wellness sector.
When did Alto Neuroscience complete a stock split?▼
Alto Neuroscience has not had any recent stock splits.
Where is Alto Neuroscience headquartered?▼
Alto Neuroscience is headquartered in MOUNTAIN VIEW, United States.